Myrobalan
Therapeutics

Myrobalan Therapeutics is a preclinical-stage biotechnology company developing novel restorative CNS therapies addressing demyelination and neuroinflammation.

A returning client from our work with Apellis Pharmaceuticals reached out to us in a new role at Myrobalan, requesting that we help them explain their novel scientific approach and create a website that can effectively communicate to investors and partners.

Drawing on our unique experience in scientific storytelling and marketing, we collaborated with the Myrobalan team to create simple mechanism of action illustrations and a comprehensive website.

We worked closely with their team, learning the intricacies of their research and helping them communicate it in a clear, sequential format using concise language and simple graphics.

The result was a modern, image-driven website with detailed illustrations of scientific mechanisms of action that seamlessly guides users through Myrobalan’s scientific strategy.

Responsive website design for Myrobalan Therapeutics, showcasing how their platform adapts to different screen sizes (desktop, tablet, mobile). The design highlights their focus on harnessing the restorative potential of novel CNS therapies, tackling neuroinflammation and promoting remyelination.
Responsive website design for Myrobalan Therapeutics, showcasing how their platform adapts to different screen sizes (desktop, tablet, mobile). The design highlights their focus on harnessing the restorative potential of novel CNS therapies, tackling neuroinflammation and promoting remyelination.
An abstract illustration representing interactions within the central nervous system, used by Myrobalan Therapeutics to visualize concepts like phagocytosis, synaptic pruning, immune activation, and re-myelination regulation.
An illustration depicting a neuron with a myelin sheath produced by oligodendrocytes, highlighting the importance of myelination for signal fidelity, axon protection, and metabolic support in the central nervous system. Used by Myrobalan Therapeutics to explain the rationale behind their remyelination therapies.